Joan's Legacy: Uniting Against Lung Cancer
27 Union Square West, Suite 304, New York, NY 10003 • ph: 212.627.5500 • fax: 212.627.7594
 
 

 

Masaaki Tamura, D.V.M., Ph.D., Kansas State University College of Veterinary Medicine: IFN-Beta Expressing Stem Cell Therapy for Bronchioalveolar Carcinoma

Epidemiological studies indicate that lung cancer is the major cause of cancer-related deaths in the United States. Bronchioalveolar  carcinoma (BAC), a subtype of lung cancer, often develops in the middle-age population without a history of tobacco smoking. Although efforts to develop early detection and subsequent surgical, chemotherapy and radiation-therapy strategies have been made, survival for subset of patients is still low. Therefore, effective new therapeutic approaches to this disease are urgently needed.

BAC usually develops at multiple sites in the airway epithelial cells. Accordingly, this study is designed to treat multiple cancer sites by targeted gene therapy which will be delivered by genetically engineered adult stem cells. Our new method will deliver cancer cell toxic gene products to the cancer tissues in a high concentration without damaging normal tissues in the body.

Adult stem cells derived from umbilical cord matrix are relatively easy to prepare in large quantity and there is no ethical issue involved in the preparation procedure, since umbilical cord is no longer useful after the delivery. In this study, we will test our hypothesis that 1) genetically engineered adult stem cells that express cancer cell toxic interferon-β are specifically delivered to BAC sites; 2) the engineered stem cell significantly attenuates cancer growth of BAC; 3) this stem cell-based therapy does not damage any normal tissue.

Our treatment strategy is significantly better than existing therapeutic strategies, including surgical therapy followed by radiation and chemotherapies since we anticipate many fewer side effects. Our stem cell-based delivery system is specific to the cancer tissues that have preliminarily been examined. Our preliminary study also demonstrated that interferon-β expressing umbilical cord stem cells significantly attenuate cancer growth of metastatic breast cancer cells. Although this study will be conducted using the mouse model, this procedure is easily applicable to human patients. Therefore, this study is feasible and our method has high potential for future human application.

 
 
Joan's Legacy is a 501(c)(3) tax-exempt organization.